Literature DB >> 27246697

Targeting the renin-angiotensin system in liver fibrosis.

Pau Sancho-Bru1, Pere Ginès2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27246697     DOI： 10.1007/s12072-016-9740-7

Source DB:  PubMed          Journal:  Hepatol Int        ISSN： 1936-0533            Impact factor:   6.047


× No keyword cloud information.
  19 in total

Review 1.  Pathophysiology of portal hypertension and its clinical links.

Authors:  Yeon Seok Seo; Vijay H Shah
Journal:  J Clin Exp Hepatol       Date:  2011-11-09

Review 2.  Liver fibrogenesis: a new role for the renin-angiotensin system.

Authors:  Ramón Bataller; Pau Sancho-Bru; Pere Ginès; David A Brenner
Journal:  Antioxid Redox Signal       Date:  2005 Sep-Oct       Impact factor: 8.401

Review 3.  Anti-fibrogenic strategies and the regression of fibrosis.

Authors:  Tatiana Kisseleva; David A Brenner
Journal:  Best Pract Res Clin Gastroenterol       Date:  2011-04       Impact factor: 3.043

4.  Attenuated hepatic inflammation and fibrosis in angiotensin type 1a receptor deficient mice.

Authors:  Liu Yang; Ramón Bataller; Jennyfer Dulyx; Thomas M Coffman; Pere Ginès; Richard A Rippe; David A Brenner
Journal:  J Hepatol       Date:  2005-08       Impact factor: 25.083

Review 5.  The role of renin-angiotensin system modulation on treatment and prevention of liver diseases.

Authors:  Simone Moreira de Macêdo; Talita Antunes Guimarães; John David Feltenberger; Sérgio Henrique Sousa Santos
Journal:  Peptides       Date:  2014-12       Impact factor: 3.750

Review 6.  The role of the renin-angiotensin system in liver fibrosis.

Authors:  M Kamruzzman Munshi; Mohammad N Uddin; Shannon S Glaser
Journal:  Exp Biol Med (Maywood)       Date:  2011-04-20

7.  Atorvastatin attenuates angiotensin II-induced inflammatory actions in the liver.

Authors:  Montserrat Moreno; Leandra N Ramalho; Pau Sancho-Bru; Marta Ruiz-Ortega; Fernando Ramalho; Juan G Abraldes; Jordi Colmenero; Marlene Dominguez; Jesús Egido; Vicente Arroyo; Pere Ginès; Ramón Bataller
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2008-12-04       Impact factor: 4.052

Review 8.  Portal hypertension.

Authors:  Andrés Cárdenas; Pere Ginès
Journal:  Curr Opin Gastroenterol       Date:  2009-05       Impact factor: 3.287

9.  Angiotensin II-induced non-alcoholic fatty liver disease is mediated by oxidative stress in transgenic TG(mRen2)27(Ren2) rats.

Authors:  Yongzhong Wei; Suzanne E Clark; E Matthew Morris; John P Thyfault; Grace M E Uptergrove; Adam T Whaley-Connell; Carlos M Ferrario; James R Sowers; Jamal A Ibdah
Journal:  J Hepatol       Date:  2008-04-22       Impact factor: 25.083

Review 10.  Liver disease and the renin-angiotensin system: recent discoveries and clinical implications.

Authors:  John S Lubel; Chandana B Herath; Louise M Burrell; Peter W Angus
Journal:  J Gastroenterol Hepatol       Date:  2008-06-28       Impact factor: 4.029
View more
  2 in total

1.  Levistilide A reverses rat hepatic fibrosis by suppressing angiotensin II‑induced hepatic stellate cells activation.

Authors:  Shu Li; Wei Zhao; Zhimin Zhao; Binbin Cheng; Shuang Li; Chenghai Liu
Journal:  Mol Med Rep       Date:  2020-07-10       Impact factor: 2.952

Review 2.  Critical Update on the Diagnosis and Management of COVID-19 in Advanced Cirrhosis and Liver Transplant Recipients.

Authors:  Cyriac Abby Philips; Mohamed Rela; Arvinder Singh Soin; Subhash Gupta; Sudhindran Surendran; Philip Augustine
Journal:  J Clin Transl Hepatol       Date:  2021-09-18
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.